PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors

Published:2016-11-04 Issue:51 Volume:7 Page:84951-84964
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Liu Minghui¹,Xu Song¹²,Wang Yuli²,Li Ying²,Li Yongwen²,Zhang Hongbing¹,Liu Hongyu²,Chen Jun¹²

Affiliation:

1. Department of Lung Cancer Surgery, Lung Cancer Institute, Tianjin Medical University General Hospital, 300052, Tianjin, China

2. Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, 300052, Tianjin, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK4 and CDK6 upregulation promotes DNA replication stress, genomic instability and resistance to EGFR targeted therapy in lung cancer;2024-03-14

2. CDK4/6 inhibitors in lung cancer: current practice and future directions;European Respiratory Review;2024-01-31

3. Bone metastasis in non-small-cell lung cancer: genomic characterization and exploration of potential targets;Therapeutic Advances in Medical Oncology;2024-01

4. CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan;Cell Cycle;2023-06-02

5. Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing;JTO Clinical and Research Reports;2022-09